Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Protalix Biotherapeutics Inc    PLX

PROTALIX BIOTHERAPEUTICS INC

(PLX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/17/2019 Date
163.3(c) 165.8(c) 167.4(c) 164.6(c) 165 Last
219 483 177 130 170 530 80 406 2 914 Volume
-3.20% +1.53% +0.97% -1.67% +0.24% Change
More quotes
Financials (USD)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 4,27x
Capi. / Sales2014 1,88x
Capitalization 67,3 M
More Financials
Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
02/06PROTALIX BIOTHERAPEUTICS : Presents Preliminary Data from the BRIGHT Study of pe..
AQ
02/05PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
02/05Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of p..
GL
01/29PROTALIX BIOTHERAPEUTICS : to Present Preliminary Data from the BRIGHT Study of ..
AQ
01/28Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of..
GL
01/10PROTALIX BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Hol..
AQ
01/04PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, ..
AQ
2018PROTALIX BIOTHERAPEUTICS : Announces the Completion of Enrollment in the Phase I..
AQ
2018PROTALIX BIOTHERAPEUTICS : PLX) Reports Complete Enrollment in Phase III BRIDGE ..
AQ
2018PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on PROTALIX BIOTHERAPEUTICS I
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS INC
Duration : Period :
Protalix Biotherapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTALIX BIOTHERAPEUTICS I
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 329%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Yaron Naos Senior Vice President-Operations
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC44.34%67
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477